Add Tribune As Your Trusted Source
TrendingVideosIndia
Opinions | CommentEditorialsThe MiddleLetters to the EditorReflections
UPSC | Exam ScheduleExam Mentor
State | Himachal PradeshPunjabJammu & KashmirHaryanaChhattisgarhMadhya PradeshRajasthanUttarakhandUttar Pradesh
City | ChandigarhAmritsarJalandharLudhianaDelhiPatialaBathindaShaharnama
World | ChinaUnited StatesPakistan
Diaspora
Features | The Tribune ScienceTime CapsuleSpectrumIn-DepthTravelFood
Business | My Money
News Columns | Straight DriveCanada CallingLondon LetterKashmir AngleJammu JournalInside the CapitalHimachal CallingHill ViewBenchmark
Don't Miss
Advertisement

Mahamaya Lifesciences Limited has secured INR 19.98 crore from seven marquee anchor investors at INR 114 per share

ANI 20251111100424

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Yearly Premium ₹999 ₹349/Year
Yearly Premium $49 $24.99/Year
Advertisement

PNN

Advertisement

Mumbai (Maharashtra) [India], November 11: Mahamaya Lifesciences Limited, an integrated agrochemical and biological solutions company, has garnered an exceptional response from marquee institutional investors in its anchor book allotment ahead of its Initial Public Offering (IPO).

Advertisement

The company has finalized the allocation of 17,52,000 equity shares to anchor investors at a price of ₹114 per equity share (including a share premium of ₹104 per share), aggregating to ₹19.98 crore.

The anchor book witnessed participation from seven high-quality institutional investors, including Abundantia Capital VCC - Abundantia Capital III, Ascend Global Opportunities Fund, Ebsu Global Opportunities Fund Limited, Vikas India EIF I Fund - Incube Global Opportunities, Aarthi AIF Growth Fund, Navbharat Investment Trust - Navbharat Investment Opportunities Fund, and Nav Capital VCC - Nav Capital Emerging Star Fund.

This robust response underscores the strong institutional confidence in Mahamaya Lifesciences business model, financial strength, and its commitment to advancing sustainable agrochemical innovation in India's evolving agri-inputs sector.

Advertisement

Managing Director's Comment

Mr. Krishnamurthy Ganesan, Managing Director, Mahamaya Lifesciences Limited, said:

"We are extremely grateful for the overwhelming trust shown by our anchor investors. Their participation reinforces our belief in the strength of our business fundamentals and our vision of driving sustainable growth in the agrochemical sector. We remain focused on expanding our capabilities, enhancing value creation, and delivering consistent performance for all stakeholders."

Merchant Banker's Comment

Mr. Akshay Kothari, OneView corporate advisors, said:

"The stellar response from marquee anchor investors is a testament to Mahamaya Lifesciences strong fundamentals, scalability, and the management's focused execution strategy. The diversity and quality of investors who have come on board highlight the high level of confidence in both the company's business model and India's agricultural growth story. We are proud to be associated with Mahamaya Lifesciences in this exciting journey."

About Mahamaya Lifesciences Limited

Mahamaya Lifesciences Limited is an integrated agrochemical and biological solutions company engaged in the manufacturing, formulation, and marketing of crop protection products for domestic and international markets. The company operates a state-of-the-art manufacturing plant at Dahej, Gujarat, with a capacity of 13 lakh litres (liquid) and 10.4 lakh kg (solid).

The company is also setting up a new technical-grade plant to enhance margins and strengthen backward integration. With a strong focus on innovation, sustainability, and efficiency, Mahamaya Lifesciences is redefining crop protection and contributing to the advancement of sustainable agriculture.

(ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN. ANI will not be responsible in any way for the content of the same.)

(This content is sourced from a syndicated feed and is published as received. The Tribune assumes no responsibility or liability for its accuracy, completeness, or content.)

Advertisement
Tags :
Advertorial DisclaimerAkshay KothariInitial Public OfferingInvestorsKrishnamurthy GanesanMahamaya LifesciencesPNN
Show comments
Advertisement